The CHMP meets once a month to review marketing applications as part of the EU’s centralized marketing procedure. CHMP opinions are sent to the European Commission, which makes a final, legally binding decision, usually within 67 days.
EU CHMP Opinions And MAA Updates
Recommendations by the European Medicines Agency’s human medicines committee (the CHMP) on the authorization of new medicines in the EU and updates on marketing authorization changes recommended by the CHMP. Updated monthly.